News
TipRanks on MSN1mon
Spyre Therapeutics Faces Compliance Hurdles After Transition from Smaller Reporting Company StatusSpyre Therapeutics, Inc (SYRE) has disclosed a new risk, in the Share Price & Shareholder Rights category. See what stocks ...
WALTHAM, Mass., April 4, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing ...
WALTHAM, Mass., March 27, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company advancing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback